About Us

Sysmex Inostics, a subsidiary of Sysmex Corporation, is a molecular diagnostic company that is a pioneer in blood-based cell-free tumor DNA (ctDNA) mutation detection in oncology utilizing highly sensitive technologies such as BEAMing (digital PCR) and SafeSEQ (NGS). These technologies were initially developed by experts at the Johns Hopkins School of Medicine over a decade ago and this deep expertise in ctDNA analysis extends to the core of Sysmex Inostics’ capabilities for technology development and implementation.

With more than 10 years’ of experience in liquid biopsy Sysmex Inostics is a trusted partner to leading pharmaceutical companies, advancing their efforts to bring the most effective personalized cancer therapies to global markets, from discovery through companion diagnostics.

Sysmex Inostics’ OncoBEAM™ and SafeSEQ services are readily available to support clinical trials and research in oncology. In addition, OncoBEAM™ tests are available through a CLIA-certified laboratory for routine clinical analysis as well as distributed kit products in the EU.

Sysmex Inostics’ European headquarters for research & development GCP laboratory testing are located in Hamburg Germany; Sysmex Inostics’ US headquarters and CLIA-certified and GCP Clinical Laboratory is located in Baltimore, Maryland. Sysmex Inostics also provides testing services in China and Japan. In addition, OncoBEAM™ assays are offered through laboratories participating in our Centers of Excellence program in Europe, Asia Pacific, and Latin America.


The Sysmex Inostics Offering

Reliable support for all phases of clinical development

Sysmex Inostics specializes in purpose-designed ultra-high sensitivity tests capable of detecting genetic alterations at very low mutant allele frequencies.
Our SafeSEQ and OncoBEAM™ testing services help ensure the most efficient approach to patient enrollment in clinical trials for targeted therapies through reliable identification of even the lowest frequency mutations.
SafeSEQ and OncoBEAM™ technologies are ideal for exploring novel clinical applications that require ultra-high sensitivity, such as molecular monitoring of minimal residual disease.

SafeSEQ Next-Generation Sequencing (NGS) services offer exquisite sensitivity, with reliable detection of 5 mutant molecules in a background of 10,000 wildtype ones (0.05% MAF). We offer expert-designed panels to answer your clinical questions accurately and efficiently.

Detect important mutations from 0.02% to 0.04% allele frequency using BEAMing enhanced digital PCR technology. OncoBEAM tests are highly clinically validated across numerous disease types to ensure unrivaled depth of information from a simple blood draw.

Choose your genes and mutations of interest with fast delivery of a custom NGS-based SafeSEQ panel to answer critical clinical questions.


Based on the highly-sensitive technologies SafeSEQ and BEAMing, we support customers with Kit products, which can be used on-site in clinically validated laboratories for identification and selection of patients for cancer type specific therapies.